Table 1. Monotherapy: randomized trials... | American Society of Hematology

Table 1.

Monotherapy: randomized trials comparing novel agents with chlorambucil.

Reference	Regimen	N	Median age, y	Advanced stage, %*	ANC, toxicity grade 3–4, %	CR, %	OR, %	PFS, mo
*Rai III-IV
**Binet C
†Study included only patients older than 65 years.
F indicates fludarabine; Clb, chlorambucil; A, alemtuzumab; B, bendamustine; ANC, absolute neutrophil count.
Rai⁴	F	179	64	39	27	20	63	20
	Clb	193	62	41	19	4	37	14
Eichhorst⁶¹	F	93	71†	36**	12	7	72	19
	Clb	100	70†	40**	12	0	51	18
Hillmen¹⁷	A	149	59	34	41	24	83	14.6
	Clb	148	60	33	25	2	55	11.7
Knauf⁹ (updated)	B	162	63	28**	23	31	68	22
	Clb	152	66	29**	11	2	31	8

Reference	Regimen	N	Median age, y	Advanced stage, %*	ANC, toxicity grade 3–4, %	CR, %	OR, %	PFS, mo
*Rai III-IV
**Binet C
†Study included only patients older than 65 years.
F indicates fludarabine; Clb, chlorambucil; A, alemtuzumab; B, bendamustine; ANC, absolute neutrophil count.
Rai⁴	F	179	64	39	27	20	63	20
	Clb	193	62	41	19	4	37	14
Eichhorst⁶¹	F	93	71†	36**	12	7	72	19
	Clb	100	70†	40**	12	0	51	18
Hillmen¹⁷	A	149	59	34	41	24	83	14.6
	Clb	148	60	33	25	2	55	11.7
Knauf⁹ (updated)	B	162	63	28**	23	31	68	22
	Clb	152	66	29**	11	2	31	8